8-K: Cerus Q2 2025 Revenue Jumps 19%, Raises Full-Year Guidance

Cerus Corporation reported strong second-quarter 2025 financial results, with total revenue increasing 19% year-over-year and product revenue up 16%, leading to a raised full-year product revenue guidance.

Summary

• Total revenue for the second quarter of 2025 was $60.1 million, an increase of 19% compared to $50.5 million in the prior year period.
• Product revenue reached a record $52.4 million in Q2 2025, up 16% year-over-year from $45.1 million.
• Government contract revenue increased 41% year-over-year to $7.7 million in Q2 2025.
• Net loss attributable to Cerus Corporation for Q2 2025 narrowed to $5.7 million, or $0.03 per basic and diluted share, from $5.8 million in Q2 2024.
• Non-GAAP adjusted EBITDA was positive $0.9 million in Q2 2025, marking another quarter of positive adjusted EBITDA.
• Cash, cash equivalents, and short-term investments stood at $78.0 million as of June 30, 2025.
• Full-year 2025 product revenue guidance was raised to a range of $200 million to $203 million, up from the previous range of $194 million to $200 million.
• Full-year 2025 INTERCEPT Fibrinogen Complex (IFC) revenue guidance was also raised to $16 million to $18 million, from $12 million to $15 million.
• Customer demand for IFC continues to increase, with Q2 IFC revenue at $5.6 million compared to $2.0 million in the prior year period.
• The company was awarded an additional $7.2 million in funding from the U.S. Department of Defense for the development of lyophilized IFC.
• The European regulatory review of the CE Mark application for the INTERCEPT Blood System for Red Blood Cells (RBCs) continues, with the dossier transferred to the State Institute for Drug Control (SKL) in the Czech Republic for consultation.

Sentiment

Score: 8

Explanation: The company demonstrated robust financial performance with significant year-over-year revenue growth, including record product sales. The upward revision of full-year product revenue and IFC guidance signals strong management confidence and positive future trajectory. Achieving positive non-GAAP adjusted EBITDA for another quarter, coupled with a narrowing net loss, indicates improving profitability and operational efficiency. The continued progress in product development (INT200 adoption, RBC CE Mark review, DoD funding for lyophilized IFC) strengthens the long-term growth prospects in a critical healthcare sector. While cash was used for operations, it was primarily for inventory to support anticipated growth, which is a healthy sign for a growing company.

Positives

• Record product revenue of $52.4 million in Q2 2025, a 16% year-over-year increase.
• Total revenue increased 19% year-over-year to $60.1 million in Q2 2025.
• Government contract revenue grew 41% year-over-year to $7.7 million, driven by increased enrollment in the Phase 3 RedeS trial and activities for the INTERCEPT RBC system.
• Net loss attributable to Cerus narrowed to $5.7 million in Q2 2025 from $5.8 million in the prior year period.
• Achieved positive non-GAAP adjusted EBITDA of $0.9 million in Q2 2025, marking another quarter of positive EBITDA.
• Full-year 2025 product revenue guidance raised to $200 million $203 million, up from the previous range of $194 million $200 million.
• Full-year 2025 INTERCEPT Fibrinogen Complex (IFC) revenue guidance raised to $16 million $18 million, up from $12 million $15 million.
• Strong customer demand for IFC, with Q2 IFC revenue at $5.6 million, significantly up from $2.0 million in the prior year.
• Awarded an additional $7.2 million in funding from the U.S. Department of Defense for the development of lyophilized IFC.
• Early launch and adoption of the next-generation, LED-based INT200 illumination device continues to surpass expectations.
• Product gross profit increased by 17% to $29.0 million in Q2 2025.

Negatives

• Cash, cash equivalents, and short-term investments decreased to $78.0 million at June 30, 2025, from $80.5 million at December 31, 2024.
• Cash used from operations totaled $2.4 million in Q2 2025, compared to $0.4 million generated in the prior year period, primarily due to an increase in working capital (inventory).
• Total operating expenses increased 18% year-over-year to $40.1 million in Q2 2025, reflecting investments but also higher R&D and SG&A expenses.
• R&D expenses increased to $18.9 million from $15.0 million, driven by INT200 development, higher government contract costs, and employee compensation.
• SG&A expenses increased to $21.2 million from $19.0 million, primarily due to higher employee compensation.

Risks

• Risks associated with the commercialization and market acceptance of, and customer demand for, the INTERCEPT Blood System, including the INT200 and INTERCEPT RBC system (if approved).
• Risks that Cerus may not realize meaningful revenue contribution from INT200 or the RBC system in the near term or at all.
• Risks associated with macroeconomic developments, including ongoing military conflicts (Ukraine, Israel/Hamas), tariffs, trade tensions, and resulting global economic and financial disruptions.
• Risks related to Cerus's ability to demonstrate to the transfusion medicine community that pathogen reduction and the INTERCEPT Blood System are safe, effective, and economical.
• Risks related to the uncertain and time-consuming development and regulatory process, including inability to obtain and maintain requisite in-country regulatory approvals for INT200 or INTERCEPT RBC system (CE Mark, FDA).
• Risks that the submission to SKL may not satisfactorily address prior issues for INTERCEPT RBC CE Mark approval.
• Risks that anticipated clinical trials may not be initiated on anticipated timing or at all, or may be extended, delayed, suspended, or terminated due to safety concerns.
• Risks associated with the uncertain nature of DoD funding, including potential delays or halts to activities if funding is adversely affected.
• Risks related to product safety.
• Risks associated with maintaining an effective, secure manufacturing supply chain, including impacts from macroeconomic developments, regulatory compliance, and ability to maintain supply agreements with third-party suppliers.
• Risks associated with the need for additional funding.
• Risks associated with the impact of legislative or regulatory healthcare reforms that may increase costs for producing, marketing, and distributing products.

Future Outlook

Cerus Corporation has raised its full-year 2025 product revenue guidance to a range of $200 million to $203 million, up from the previous $194 million to $200 million, reflecting strong first-half performance and anticipated second-half growth. The company also increased its 2025 INTERCEPT Fibrinogen Complex (IFC) revenue guidance to $16 million to $18 million, from $12 million to $15 million. Cerus remains committed to achieving positive, full-year 2025 non-GAAP adjusted EBITDA. The European regulatory review for the INTERCEPT Blood System for Red Blood Cells (RBCs) is ongoing, with the dossier transferred to the State Institute for Drug Control (SKL) in the Czech Republic for consultation.

Management Comments

• "With our singular focus to advance blood safety and availability around the globe by establishing INTERCEPT as the standard of care, this quarter's commercial results are evidence of the progress we are making in multiple geographies and across our INTERCEPT product portfolio."
• "The early launch and adoption of our next generation, LED-based INT200 illumination device continues to surpass our expectations around performance and customer experience, and advancements in our product development pipeline are encouraging, including the early resubmission for RBC CE Mark and the recent DoD award for the CRYO-First study."
• "In addition, the continued strong commercial and financial execution in Q2 resulted in record product sales, a year-over-year narrowing of net loss attributable to Cerus, and another quarter of positive non-GAAP adjusted EBITDA."
• "Given the anticipated sales trajectory, we are raising our full-year 2025 product revenue guidance today."
• "The Company remains committed to its goal of achieving positive, full-year 2025 non-GAAP adjusted EBITDA."

Industry Context

Cerus operates in the specialized field of blood safety and pathogen reduction, aiming to establish its INTERCEPT system as the standard of care globally. The continued growth in product revenue, particularly for INTERCEPT Fibrinogen Complex (IFC) and global platelet sales, indicates increasing adoption of pathogen-reduced blood components. The development of next-generation technologies like the LED-based INT200 and the ongoing regulatory review for Red Blood Cells (RBCs) position Cerus to expand its market presence and address broader needs in transfusion medicine. The DoD funding for lyophilized IFC development highlights the strategic importance of advanced blood products for military and emergency applications, aligning with broader trends in national preparedness and supply chain resilience for critical medical supplies.

Stakeholder Impact

• Shareholders: Positive impact due to strong financial performance, record product sales, narrowed net loss, positive adjusted EBITDA, and raised full-year revenue guidance, potentially leading to increased share value.
• Customers (Blood Centers, Hospitals): Continued availability and advancement of INTERCEPT products (platelets, plasma, IFC, and future RBCs) enhance blood safety and availability, improving patient care.
• Employees: Increased R&D and SG&A expenses, partly due to higher employee compensation tied to cost-of-living adjustments, suggest continued investment in the workforce.
• Regulatory Authorities: Ongoing engagement with European regulatory bodies (TV-SD, SKL) for INTERCEPT RBC CE Mark application.
• U.S. Department of Defense: Continued partnership and additional funding for lyophilized IFC development support national defense and emergency preparedness.

Next Steps

• Continue European regulatory review process for INTERCEPT Blood System for Red Blood Cells (RBCs) with the State Institute for Drug Control (SKL) in the Czech Republic.
• Advance development of lyophilized INTERCEPT Fibrinogen Complex (IFC) with the additional $7.2 million in DoD funding.
• Continue to drive future revenue growth through investments in R&D and SG&A.
• Work towards achieving positive, full-year 2025 non-GAAP adjusted EBITDA.
• Host a conference call on August 5, 2025, at 4:30 P.M. ET to discuss financial results and provide a business overview and outlook.

Key Dates

Recommendation

The company demonstrated robust financial performance with significant year-over-year revenue growth, including record product sales. The upward revision of full-year product revenue and IFC guidance signals strong management confidence and positive future trajectory. Achieving positive non-GAAP adjusted EBITDA for another quarter, coupled with a narrowing net loss, indicates improving profitability and operational efficiency. The continued progress in product development (INT200 adoption, RBC CE Mark review, DoD funding for lyophilized IFC) strengthens the long-term growth prospects in a critical healthcare sector. While cash was used for operations, it was primarily for inventory to support anticipated growth, which is a healthy sign for a growing company. These factors collectively suggest a strong investment opportunity.

Keywords

Cerus Corporation, CERS, Financial Results, Q2 2025, Product Revenue, INTERCEPT Blood System, Pathogen Reduction, Blood Safety, INTERCEPT Fibrinogen Complex, IFC, INTERCEPT RBC, INT200, Biotechnology, Medical Devices, SEC Filing, Earnings Report, Guidance Update